During the reporting period, the project revenue of Medicilon in accordance with both Chinese and American accounting standards amounted to RMB 277 million, accounting for 31.79% of the company's main operating revenue.
Revenue from overseas clients was RMB 226 million, accounting for 25.88% of the main operating revenue.
During the reporting period, the research of 45 new drugs and generic drug projects participated by Medicilon have been approved by NMPA for clinical trials, 10 projects have been approved by the US FDA for clinical trials.
Share：
Relevant news
marketing@medicilon.com
